Literature DB >> 10376768

Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene.

E Lévesque1, M Beaulieu, D W Hum, A Bélanger.   

Abstract

Variations in glucuronidation activities among different individuals have been reported; however, genetic polymorphisms in the genes encoding phase II drug metabolizing UDP-glucuronosyltransferases have not been studied extensively. A novel UGT2B cDNA clone UGT2B4(E458) was isolated from human prostate and LNCaP cell cDNA libraries. The cDNA encoding UGT2B4(E458) is 2097 bp in length and has an open reading frame of 1584 nucleotides encoding a protein of 528 amino acids. Characterization of the UGT2B4(E458) cDNA revealed nucleotide differences with the previously published UGT2B4 and UGT2B11 cDNAs. These variations in the UGT2B4 sequence lead to an amino acid change from aspartic acid to glutamic acid at position 458. In the previous UGT2B11 cDNA (which has subsequently been renamed UGT2B4 (L109,396, D458)), leucine residues are found at positions 109 and 396, whereas phenylalanines are present at these positions in the UGT2B4(D458) and UGT2B4(E458) enzymes. Analysing the genomic DNA of 26 unrelated Caucasian individuals demonstrated the presence of variant alleles encoding UGT2B4(D458) and UGT2B4(E458). Stable expression of UGT2B4(E458) cDNA in HK293 cells demonstrates the presence of a 52 kDa protein, which is in agreement with other characterized (UGT2B proteins. UGT2B4(E458) conjugates hyodeoxycholic acid (HDCA) as well as 4-hydroxyestrone (4-OH-E1), androstane-3alpha,17beta-diol (3alpha-diol) and androsterone (ADT). Specific reverse transcriptase-polymerase chain reaction analysis revealed expression of UGT2B4(D458) and UGT2B4(E458) transcripts in a wide range of extrahepatic tissues, including the liver, kidney, testis, mammary gland, prostate, placenta, adipose, adrenal, skin and lung. Our results suggest that UGT2B4(E458) and UGT2B(E458) are two widely expressed isoenzymes, and that polymorphism in the UGT2B4 gene might be responsible for differences in UGT2B4 enzymatic properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376768

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  12 in total

1.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

2.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

3.  Cellular asymmetric catalysis by UDP-glucuronosyltransferase 1A8 shows functional localization to the basolateral plasma membrane.

Authors:  Kerstin Ziegler; Sarka Tumova; Asimina Kerimi; Gary Williamson
Journal:  J Biol Chem       Date:  2015-01-13       Impact factor: 5.157

Review 4.  Lipid-activated transcription factors control bile acid glucuronidation.

Authors:  Olivier Barbier; Jocelyn Trottier; Jenny Kaeding; Patrick Caron; Mélanie Verreault
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

5.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Authors:  Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus
Journal:  Genes Chromosomes Cancer       Date:  2014-06       Impact factor: 5.006

Review 6.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.

Authors:  Philip Lazarus; Andrea S Blevins-Primeau; Yan Zheng; Dongxiao Sun
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

7.  Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity.

Authors:  Masaru Iwai; Yoshihiro Maruo; Masaki Ito; Kazuo Yamamoto; Hiroshi Sato; Yoshihiro Takeuchi
Journal:  J Hum Genet       Date:  2004-02-18       Impact factor: 3.172

8.  Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8.

Authors:  Syed Muzeeb; Shaik Jafar Sadik Basha; Dhanya Shashikumar; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Oct-Dec       Impact factor: 2.569

9.  UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.

Authors:  Rachel Sparks; Cornelia M Ulrich; Jeannette Bigler; Shelley S Tworoger; Yutaka Yasui; Kumar B Rajan; Peggy Porter; Frank Z Stanczyk; Rachel Ballard-Barbash; Xiaopu Yuan; Ming Gang Lin; Lynda McVarish; Erin J Aiello; Anne McTiernan
Journal:  Breast Cancer Res       Date:  2004-06-29       Impact factor: 6.466

10.  Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.

Authors:  J Trottier; M Perreault; I Rudkowska; C Levy; A Dallaire-Theroux; M Verreault; P Caron; B Staels; M-C Vohl; R J Straka; O Barbier
Journal:  Clin Pharmacol Ther       Date:  2013-06-12       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.